Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats severe asthma. Sold as Tezspire. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Tezepelumab-Ekko (sold as Tezspire), first approved Dec 17, 2021, with 2 new uses approved and 0 published complete response letters.
First approved: Dec 17, 2021
Applications: 1
New uses approved: 2
Complete response letters: 0
Medicare spending, 2025: $682M
First approved in the EU: Sep 19, 2022
First approved in Japan: Sep 26, 2022
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
First approved in Japan 9 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
TezspireDrugs with a new indication and a new dosage for the treatment of chronic rhinosinusitis with nasal polyps (for use only in patients who have not responded… · AstraZeneca K.K. · Feb 19, 2026
Tezspire, new ingredientA drug with a new active ingredient indicated for the treatment of bronchial asthma (for use only in patients with severe or intractable bronchial asthma… · AstraZeneca K.K. · Sep 26, 2022
Clinical Trials
1 open or ongoing study names this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Astrazeneca AB